Ftse Mib
34.326,90
0,51%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.475,21
2,10%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ KALA BIO Inc (KALA) KALA BIO Inc (KALA) Notizie

KALA

KALA BIO (KALA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KALA
DataOraFonteTitoloSimboloCompagnia
29/03/202413:00GlobeNewswire Inc.KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
04/03/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALAKALA BIO Inc
26/02/202414:00GlobeNewswire Inc.KALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceNASDAQ:KALAKALA BIO Inc
14/02/202419:09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KALAKALA BIO Inc
06/02/202414:00GlobeNewswire Inc.KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:KALAKALA BIO Inc
19/01/202422:01GlobeNewswire Inc.KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALAKALA BIO Inc
05/01/202422:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALAKALA BIO Inc
13/11/202314:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALAKALA BIO Inc
13/11/202314:00GlobeNewswire Inc.KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
18/10/202322:04Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:KALAKALA BIO Inc
05/09/202314:00GlobeNewswire Inc.KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KALAKALA BIO Inc
04/08/202314:00GlobeNewswire Inc.KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
02/08/202322:01GlobeNewswire Inc.KALA BIO to Participate in Upcoming Investor Conferences in AugustNASDAQ:KALAKALA BIO Inc
02/08/202314:00GlobeNewswire Inc.Kala Pharmaceuticals Announces Name Change to KALA BIONASDAQ:KALAKALA BIO Inc
19/07/202322:01GlobeNewswire Inc.Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALAKALA BIO Inc
23/06/202322:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KALAKALA BIO Inc
22/06/202322:48Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KALAKALA BIO Inc
15/06/202317:58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:KALAKALA BIO Inc
02/06/202314:00GlobeNewswire Inc.Kala Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:KALAKALA BIO Inc
31/05/202322:03Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:KALAKALA BIO Inc
11/05/202323:26Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KALAKALA BIO Inc
09/05/202314:00GlobeNewswire Inc.Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:KALAKALA BIO Inc
28/04/202314:00GlobeNewswire Inc.Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCEDNASDAQ:KALAKALA BIO Inc
12/04/202314:00GlobeNewswire Inc.Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial DefectNASDAQ:KALAKALA BIO Inc
29/03/202314:00GlobeNewswire Inc.Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical AdvisorNASDAQ:KALAKALA BIO Inc
27/03/202314:00GlobeNewswire Inc.Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCEDNASDAQ:KALAKALA BIO Inc
15/03/202311:43Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:KALAKALA BIO Inc
08/03/202322:01GlobeNewswire Inc.Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:KALAKALA BIO Inc
03/03/202322:13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:KALAKALA BIO Inc
03/03/202314:17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:KALAKALA BIO Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KALA

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network